US Patent Issued to Dana-Farber Cancer Institute on March 3 for "HCK as a therapeutic target in MYD88 mutated diseases" (American, Chinese Inventors)

ALEXANDRIA, Va., March 3 -- United States Patent no. 12,564,591, issued on March 3, was assigned to Dana-Farber Cancer Institute Inc. (Boston).

"HCK as a therapeutic target in MYD88 mutated diseases" was invented by Steven P. Treon (Jamaica Plain, Mass.), Guang Yang (Natick, Mass.), Jinhua Wang (Winchester, Mass.), Li Tan (Shanghai), Nathanael S. Gray (Stanford, Calif.) and Sara Jean Buhrlage (Somerville, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are methods of treating diseases (e.g., proliferative disease (e.g., cancer (e.g., breast cancer, colon cancer, testicular cancer, CNS cancer, stomach cancer, lymphoma (e.g., B-cell lymphoma (e.g., lymphoplasmacytic lymphoma (e.g., IgM sec...